HLA-C

Overview

HLA-C (Human Leukocyte Antigen C) is an MHC class I molecule essential for presenting intracellular peptides to cytotoxic T cells. Somatic mutations in HLA class I genes (HLA-A, HLA-B, HLA-C) are a mechanism of immune escape in cancer, allowing tumor cells to evade T cell-mediated killing. HLA-C mutations are particularly relevant to neoantigen presentation and response to immune checkpoint inhibitors.

Alterations observed in the corpus

  • Part of the HLA class I (HLA-A/B/C) somatic mutation cluster found in 11% of colorectal cancer cases in a 619-sample neoantigen study; mutations biased toward exon 4 (TCR-binding domain) and peptide-contact residues in exons 2-3; mutated alleles carry more neoantigens than non-mutated alleles (Wilcoxon p=0.006); collectively enriched for immune-escape selection in TIL-rich tumors PMID:26997480

Cancer types (linked)

Co-occurrence and mutual exclusivity

Therapeutic relevance

Open questions

Sources

This page was processed by crosslinker on 2026-05-14.